Indication
Epidermolysis Bullosa Dystrophica
11 clinical trials
11 products
Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Pilot Stage Clinical Trial Evaluating CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis BullosaStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Beremagene GeperpavecClinical trial
Open Label Treatment of Beremagene Geperpavec (B-VEC)Status: Completed, Estimated PCD: 2023-07-31
Clinical trial
Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) PatientsStatus: Recruiting, Estimated PCD: 2025-10-01
Product
ALLO-ASC-SHEETProduct
AGLE 102Clinical trial
A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa WoundsStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)Status: Completed, Estimated PCD: 2021-10-29
Clinical trial
A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)Status: Completed, Estimated PCD: 2019-11-01
Product
PTW-002Clinical trial
A Double-blind, Randomized, Intra-patient Placebo- Controlled, Multiple Dose Study of PTW-002 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy, and Systemic Exposure in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa (DDEB / RDEB) Due to Mutation(s) in Exon 73 of the COL7A1 GeneStatus: Not yet recruiting, Estimated PCD: 2024-04-30
Product
ALLO-ASC-DFUClinical trial
A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101Status: Completed, Estimated PCD: 2018-04-20
Clinical trial
A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis BullosaStatus: Completed, Estimated PCD: 2023-04-03
Product
Vehicle CreamProduct
INM-755Clinical trial
A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
RigosertibClinical trial
SASS 3: Self-Assembled Skin Substitute (SASS) for the Treatment of Epidermolysis BullosaStatus: Active (not recruiting), Estimated PCD: 2019-12-24
Product
SASS